Vir Biotechnology (VIR) Stock Forecast & Price Target

Compare

1,358 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VIR Analyst Ratings

Strong Buy

7 Buy

2 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Vir

Biotechnology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$18.14

▲(234.07%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $18.14 with a high forecast of $31.00 and a low forecast of $12.00. The average price target represents a 234.07% change from the last price of $5.43.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","25":"$25","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,11,18,25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,7.064615384615385,9.05923076923077,11.053846153846155,13.048461538461538,15.043076923076924,17.03769230769231,19.032307692307693,21.026923076923076,23.021538461538462,25.01615384615385,27.01076923076923,29.005384615384617,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,6.075384615384616,7.080769230769231,8.086153846153845,9.091538461538462,10.096923076923076,11.102307692307692,12.107692307692307,13.113076923076923,14.118461538461538,15.123846153846154,16.12923076923077,17.134615384615383,{"y":18.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.07,5.603076923076923,6.136153846153846,6.6692307692307695,7.202307692307692,7.735384615384615,8.268461538461539,8.801538461538462,9.334615384615384,9.867692307692307,10.40076923076923,10.933846153846154,11.466923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.24,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.27,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$31.00

Average Price Target$18.14

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

1.29%

Upside

Reiterated

07/03/25

Vir Biotechnology's overall score reflects financial volatility and strategic challenges. The company's strong cash position and advancements in disease programs offer potential for future growth, but current financial instability and reliance on partnerships pose significant risks.

Alec StranahanBank of America Securities

Bank of America Securities

$12

Hold

120.99%

Upside

Reiterated

06/26/25

Bank of America Securities Reaffirms Their Hold Rating on Vir Biotechnology (VIR)

Roanna RuizLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/02/25

Positive Outlook on Vir Biotechnology's VIR-5500 Amid Competitive mCRPC Market

Joseph StringerNeedham

Needham

$14

Buy

157.83%

Upside

Reiterated

05/22/25

Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), Genmab (NASDAQ: GMAB) and Vir Biotechnology (NASDAQ: VIR)

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$110→$15

Buy

176.24%

Upside

Reiterated

05/20/25

Vir Biotechnology price target lowered to $15 from $110 at H.C. WainwrightVir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright

Gena WangBarclays

Barclays

$31

Buy

470.90%

Upside

Reiterated

05/08/25

Vir Biotechnology (VIR) Gets a Buy from Barclays

Phil NadeauTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Vir Biotechnology: Strong Financials and Promising Pipeline Justify Buy Rating

Michael UlzMorgan Stanley

Morgan Stanley

$20

Buy

268.32%

Upside

Reiterated

05/08/25

Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Vir Biotechnology (VIR)

Eric JosephJ.P. Morgan

J.P. Morgan

$14

Hold

157.83%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul ChoiGoldman Sachs

Goldman Sachs

$28→$21

Buy

286.74%

Upside

Reiterated

04/16/25

Vir Biotechnology (VIR) PT Lowered to $21 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $21.00 (from $28.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$5.5

Hold

1.29%

Upside

Reiterated

07/03/25

Alec StranahanBank of America Securities

Bank of America Securities

$12

Hold

120.99%

Upside

Reiterated

06/26/25

Bank of America Securities Reaffirms Their Hold Rating on Vir Biotechnology (VIR)

Roanna RuizLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/02/25

Positive Outlook on Vir Biotechnology's VIR-5500 Amid Competitive mCRPC Market

Joseph StringerNeedham

Needham

$14

Buy

157.83%

Upside

Reiterated

05/22/25

Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), Genmab (NASDAQ: GMAB) and Vir Biotechnology (NASDAQ: VIR)

Patrick TrucchioH.C. Wainwright

H.C. Wainwright

$110→$15

Buy

176.24%

Upside

Reiterated

05/20/25

Vir Biotechnology price target lowered to $15 from $110 at H.C. WainwrightVir Biotechnology price target lowered to $15 from $110 at H.C. Wainwright

Gena WangBarclays

Barclays

$31

Buy

470.90%

Upside

Reiterated

05/08/25

Vir Biotechnology (VIR) Gets a Buy from Barclays

Phil NadeauTD Cowen

TD Cowen

―

Buy

―

Reiterated

05/08/25

Vir Biotechnology: Strong Financials and Promising Pipeline Justify Buy Rating

Michael UlzMorgan Stanley

Morgan Stanley

$20

Buy

268.32%

Upside

Reiterated

05/08/25

Analysts Are Bullish on Top Healthcare Stocks: Lifestance Health Group (LFST), Vir Biotechnology (VIR)

Eric JosephJ.P. Morgan

J.P. Morgan

$14

Hold

157.83%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul ChoiGoldman Sachs

Goldman Sachs

$28→$21

Buy

286.74%

Upside

Reiterated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

1 Month

xxx

Success Rate

8/21 ratings generated profit

Average Return

-6.58%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 38.10% of your transactions generating a profit, with an average return of -6.58% per trade.

3 Months

xxx

Success Rate

9/22 ratings generated profit

Average Return

-9.47%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 40.91% of your transactions generating a profit, with an average return of -9.47% per trade.

1 Year

Gena WangBarclays

Success Rate

6/22 ratings generated profit

Average Return

-17.58%

reiterated a buy rating 2 months ago

Copying Gena Wang's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -17.58% per trade.

2 Years

xxx

Success Rate

3/22 ratings generated profit

Average Return

-35.62%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.64% of your transactions generating a profit, with an average return of -35.62% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VIR has received 11 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 18.14.

Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is -$0.70 with a range of -$0.78 to -$0.54. The previous quarter’s EPS was -$0.88. VIR beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year VIR has Preformed in-line its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $2.66M with a range of $0.00 to $5.00M. The previous quarter’s sales results were $3.03M. VIR beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.53% of the time in the same period. In the last calendar year VIR has Preformed in-line its overall industry.

VIR Stock Forecast FAQ

What is VIR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vir Biotechnology’s 12-month average price target is 18.14.

What is VIR’s upside potential, based on the analysts’ average price target?

Vir Biotechnology has 234.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VIR a Buy, Sell or Hold?

Vir Biotechnology has a consensus rating of Strong Buy which is based on 7 buy ratings, 2 hold ratings and 0 sell ratings.

What is Vir Biotechnology’s price target?

The average price target for Vir Biotechnology is 18.14. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $12.00. The average price target represents 234.07% Increase from the current price of $5.43.

What do analysts say about Vir Biotechnology?

Vir Biotechnology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of VIR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vir Biotechnology (VIR) Stock Forecast & Price Target

VIR Analyst Ratings

VIR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vir Biotechnology

VIR Analyst Recommendation Trends

VIR Financial Forecast

VIR Earnings Forecast

VIR Sales Forecast

VIR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts